ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism

Duration of Rapamycin Treatment Has Differential Effects on Metabolism in Mice

(2013) Yimin Fang et al.   Cell Metabolism

Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia

(2013) Valérie Bernard et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

(2012) P. Reichardt et al.   ANNALS OF ONCOLOGY

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Mechanistic target of rapamycin inhibitors in solid organ transplantation

(2012) Maxime Touzot et al.   Current Opinion in Organ Transplantation

Impact of Sunitinib Treatment on Blood Glucose Levels in Patients with Metastatic Renal Cell Carcinoma

(2012) J. J. Oh et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice

(2012) Ding Ai et al.   JOURNAL OF CLINICAL INVESTIGATION

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

(2012) Naifa L. Busaidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

(2012) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

(2012) David Neal Franz et al.   LANCET

mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes

(2012) Maria J. Pereira et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

(2012) D. W. Lamming et al.   SCIENCE

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway

(2011) Timothy R. Peterson et al.   CELL

Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbidities

(2011) P. Valent   HAEMATOLOGICA

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid Profile Changes During the First Year After Kidney Transplantation: Risk Factors and Influence of the Immunosuppressive Drug Regimen

(2011) G.A. Spinelli et al.   TRANSPLANTATION PROCEEDINGS

Efficacy and Safety of Sirolimus and Everolimus in Heart Transplant Patients: A Retrospective Analysis

(2011) B. Baur et al.   TRANSPLANTATION PROCEEDINGS

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

(2010) V. P. Houde et al.   DIABETES

Endocrine side effects of broad-acting kinase inhibitors

(2010) Maya B Lodish et al.   ENDOCRINE-RELATED CANCER

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

mTORC1 controls fasting-induced ketogenesis and its modulation by ageing

(2010) Shomit Sengupta et al.   NATURE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of Side Effects of Sirolimus Therapy

(2010) Giovanni Stallone et al.   TRANSPLANTATION

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy

(2009) Ian G. Ganley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Glycemic Control in Patients with Insulinoma Treated with Everolimus

(2009) Matthew H. Kulke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway

(2009) Hui H. Zhang et al.   PLoS One

Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

(2008) B. L. Kasiske et al.   AMERICAN JOURNAL OF TRANSPLANTATION

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

(2008) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib

(2008) B Billemont et al.   BRITISH JOURNAL OF CANCER

SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth

(2008) Thomas Porstmann et al.   Cell Metabolism

Regulation of Ceramide Biosynthesis by TOR Complex 2

(2008) Sofia Aronova et al.   Cell Metabolism

Skeletal Muscle-Specific Ablation of raptor, but Not of rictor, Causes Metabolic Changes and Results in Muscle Dystrophy

(2008) C. Florian Bentzinger et al.   Cell Metabolism

mTOR Inhibition by Rapamycin Prevents  -Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes

(2008) M. Fraenkel et al.   DIABETES

Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients

(2008) O. Johnston et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Biphasic Response of Pancreatic  -Cell Mass to Ablation of Tuberous Sclerosis Complex 2 in Mice

(2008) Y. Shigeyama et al.   MOLECULAR AND CELLULAR BIOLOGY

Disruption of Tsc2 in pancreatic   cells induces   cell mass expansion and improved glucose tolerance in a TORC1-dependent manner

(2008) L. Rachdi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PCSK9 and LDL cholesterol: unravelling the target to design the bullet

(2008) Philippe Costet et al.   TRENDS IN BIOCHEMICAL SCIENCES